Lipid-Therapie – warum, für wen und wie intensiv?

Praxis (Bern 1994). 2017 Aug;106(17):921-926. doi: 10.1024/1661-8157/a002757.
[Article in German]
No abstract available

Keywords: Cholestérol LDL; LDL cholesterol; LDL-Cholesterin; PCSK9 inhibitors; PCSK9-Inhibitoren; Statine; cardiovascular risk; inhibiteurs de la PCSK9; kardiovaskuläres Risiko; risque cardiovasculaire; statines; statins.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Algorithms
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Dyslipidemias / blood
  • Dyslipidemias / diagnosis
  • Dyslipidemias / drug therapy*
  • Female
  • Guideline Adherence
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / diagnosis
  • Hypercholesterolemia / drug therapy
  • Male
  • Middle Aged
  • PCSK9 Inhibitors*
  • Risk

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • PCSK9 Inhibitors
  • PCSK9 protein, human